Angiolymphoid Hyperplasia With Eosinophilia—Combination Treatment With Propranolol and Surgical Resection

Zarbafian, Misha; Ward, Chloé; Zhang, Jing; Macdonald, Jillian

doi:10.1097/dss.0000000000001442

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the first study to assess the use of PES for patients with ALHE. Interestingly, a few previous case reports and small case series have reported intralesional chemotherapy with bleomycin (two patients) and sclerotherapy with polidocanol (case report and case series of three patients) to be effective in ALHE 7–9 . In our study, only 1–2 treatment sessions with PES were required to obtain ‘excellent’ improvement as rated by independent outcome assessors, compared with 5–7 treatments with the previously used sclerosants (except for a single case treated only once).…”

Section: Reportmentioning

confidence: 55%

Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia

Galili

Levi

Lapidoth

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

Summary Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign vascular proliferation, which manifests as characteristic red nodules and papules, mostly located on the scalp and periauricular regions. Patients seek treatment for both aesthetic and functional reasons, as lesions may ulcerate, bleed and itch. Many therapeutic approaches have been reported, with variable success, and relapse remains a troublesome issue. The aim of this study was to report our experience treating ALHE using percutaneous ethanol sclerotherapy (PES). We present a retrospective case series of three patients treated with PES (1–2 treatment sessions each). All patients had tried and failed other treatments prior to this intervention, but following PES treatment, all patients demonstrated significant improvement, which was sustained at follow‐up (range 8–17 months after first treatment). Adverse effects were tolerable and transient. This case series demonstrates PES as a promising treatment for recalcitrant ALHE.

show abstract

Section: Reportmentioning

confidence: 55%

Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia

Galili

Levi

Lapidoth

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

show abstract

“…Oral propranolol and topical beta-blockers are an established treatment for proliferating infantile hemangiomas due to vasoconstrictive and angiogenesis-inhibiting effects. 3 , 4 Similarly, there are case reports of propranolol improving other vascular diseases such as arteriovenous malformations, 3 cavernous hemangioma, 5 angiolymphoid hyperplasia with eosinophilia, 6 pyogenic granuloma, 7 angiosarcoma, 8 KS, 9 and other reactive angiomatoses (reactive angioendotheliomatosis and graft-versus-host disease-associated angiomatosis). 4 Regression of classic KS lesions treated with topical β-blocker has been noted.…”

Section: Discussionmentioning

confidence: 99%

A case of bilateral plantar pseudo-Kaposi sarcoma successfully treated with propranolol

et al. 2021

View full text Add to dashboard Cite

Ophthalmic Manifestations of Angiolymphoid Hyperplasia with Eosinophilia: A Systematic Review and Pooled Analysis of 86 Cases

Ahmed,

Thrishulamurthy,

Venkatesh

et al. 2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: This systematic review aims to consolidate evidence on ophthalmological manifestations of angiolymphoid hyperplasia with eosinophilia, focusing on its presentation, diagnosis, and management. Methods: Preferred reporting items for systematic reviews and meta-analyses-adherent systematic review was conducted across 3 databases from inception until September 2024. Case reports and series detailing angiolymphoid hyperplasia with eosinophilia in ocular structures were included. Data on demographics, clinical presentation, diagnostic methods, and treatment outcomes were extracted and analyzed. Results: A total of 86 patients from 52 case reports/series were included. The median age was 41 years (IQR: 22–54), with a slight male predominance (51.16%, n = 44/86). The majority of patients (94.18%, n = 81/86) presented with unilateral eye involvement. The orbit was the most frequently involved location (45.35%, n = 39/86), followed by the upper eyelid (27.91%, n = 24/86). Clinical symptoms included proptosis (36.04%, n = 31/86), ptosis (26.74%, n = 23/86), and diplopia (11.67%, n = 10/86). Surgical excision was performed in 54.65% (n = 47/86) of cases, with biopsy done for diagnostic purposes in all patients. Recurrence occurred in 13.95% (n = 12/86), with risk factors including incomplete excision and prior angiolymphoid hyperplasia with eosinophilia in the same or opposite eye. Steroid therapy was used in 18.6% (n = 16/86) but showed limited success. Newer treatment strategies with propranolol showed efficacy in recurrent cases, with no recurrence reported in patients receiving this therapy. Conclusion: Angiolymphoid hyperplasia with eosinophilia in ocular structures presents diagnostic and therapeutic challenges. Surgical excision remains the mainstay of treatment, though recurrence is common. Therapeutic strategies with propranolol may offer alternative management options in recurrent cases.

show abstract

Angiolymphoid Hyperplasia With Eosinophilia—Combination Treatment With Propranolol and Surgical Resection

Cited by 4 publications

References 5 publications

Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia

Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia

A case of bilateral plantar pseudo-Kaposi sarcoma successfully treated with propranolol

Ophthalmic Manifestations of Angiolymphoid Hyperplasia with Eosinophilia: A Systematic Review and Pooled Analysis of 86 Cases

Contact Info

Product

Resources

About